OPEN ACCESS Freely available online

ISSN: 2161-1041
Hereditary Genetics: Current Research

Perspective

Fibrocystin and its Impact on Renal Cystogenesis in Autosomal Recessive Polycystic Kidney Disease ARPKD

Madoka Fukunaga*

Department of Genetics, Nihon University, Tokyo, Japan

DESCRIPTION

Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a rare but toxic genetic disorder that affects the kidneys. The key gene product involved in this condition is fibrocystin, a large Tran's membrane protein. Understanding the molecular structure and function of fibrocystin is acute in solving the mechanisms of ARPKD and may hold the key to future therapeutic interventions. Fibrocystin is encoded by the *PKHD1* gene, which is located on chromosome 6. The gene lengths approximately 470 kb and consists of 86 exons. The fibrocystin protein is immense, with a molecular weight of about 447 kDa. Its size alone suggests the complex nature of its structure and function. The protein exhibits a multi-domain structure that plays a key role in its various functions. The N-terminal region of fibrocystin contains a signal peptide, which directs the protein to the endoplasmic reticulum, where it undergoes post-translational processing.

Fibrocystin is glycosylated, and these sugar components may serve as identification sites for protein-protein interactions. One of the prominent features of fibrocystin is the presence of multiple immunoglobulin-like domains (Ig-like domains) in its extracellular region. These Ig-like domains mediate cell-cell adhesion, an acute function in the formation and maintenance of tubular structures in the kidneys. Disruptions in cell adhesion can lead to the cystic dilation of renal tubules seen in ARPKD. The C-terminal part of fibrocystin contains a single-pass transmembrane domain and an intracellular tail. The transmembrane domain anchors fibrocystin in the plasma membrane of kidney epithelial cells, while the intracellular back interacts with various signaling proteins and cytoskeletal elements. These interactions are essential for cell signaling and maintaining cellular architecture. Fibrocystin serves as a multifunctional protein in the kidney, and its role in ARPKD pathology is multifaceted. The Ig-like domains in fibrocystin facilitate cell-cell adhesion and contribute to the structural integrity of renal tubules. Loss of functional fibrocystin disrupts tubulogenesis and leads to cyst formation in the kidneys.

Fibrocystin is involved in the control of cyst growth through its interaction with intracellular signaling pathways. It can influence cell proliferation, apoptosis, and fluid secretion, all of which play a role in the expansion of renal cysts in ARPKD. Fibrocystin has been proposed to act as a mechanosensory protein, responding to changes in fluid flow within renal tubules. This mechanosensory function could influence various cellular processes in response to fluid dynamics, possibly contributing to cyst formation. Fibrocystin interacts with polycystin-2, a protein linked to another form of polycystic kidney disease. This interaction is thought to be acute for ciliary function and signaling, further emphasizing the complex network of proteins involved in renal cytogenesis. Fibrocystin may also play a role in EMT, a process where renal tubular cells lose their epithelial characteristics and acquire a more mesenchymal phenotype. This transition is involved in cyst development and fibrosis in ARPKD.

CONCLUSION

The molecular structure and function of fibrocystin, the key gene product involved in ARPKD, is complex and multifaceted. Its vast size, complex domain structure, and role in various cellular processes underscore its significance in kidney development and homeostasis. Understanding how fibrocystin contributes to ARPKD pathology at the molecular level is acute for developing targeted therapies and interventions to alleviate the suffering of individuals affected by this devastating disease. Further research into the interactions and functions of fibrocystin may provide valuable insights into the development of treatments for ARPKD, ultimately providing hope to those impacted by this rare genetic disorder.

Correspondence to: Madoka Fukunaga, Department of Genetics, Nihon University, Tokyo, Japan, E-mail: mdkfkn@gmail.com

Received: 06-Nov-2023, Manuscript No. HGCR-23-24423; **Editor assigned:** 08-Nov-2023, Pre QC No. HGCR-23-24423 (PQ); **Reviewed:** 30-Nov-2023, QC No. HGCR-23-24423; **Revised:** 07-Dec-2023, Manuscript No. HGCR-23-24423 (R); **Published:** 14-Dec-2023, DOI: 10.35248/2161-1041.23.12.262

Citation: Fukunaga M (2023) Fibrocystin and its Impact on Renal Cystogenesis in Autosomal Recessive Polycystic Kidney Disease ARPKD. Hereditary Genet.12:262.